SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
Bullish on AOB ...
AOB
|
|
|
-2.20%
in
12 days
American Oriental Bioengineering, Inc. (NYSE: AOB a pharmaceutical company announced that it plans to release third quarter 2009 financial results on Monday, November 16, 2009, after the market closes. <> On CAPS, 97% of the 3,140 members rated this stock to outperform the S&P 500 going forward and this stock is not rated on CAPS for nothing " Companies in China will continue to grow, even the poorly run ones, simply due to the massive socio-economic shift of the growing Chinese middle class. As people acquire wealth, the number one place they put it is in securing health (their own, <><><><><><><><><><>< /><><><><><><><><><><><><>< />...
|
Time to channel back up
AOB
|
|
|
+4.11%
in
97 days
(closed on 01/05/09)
Together with its subsidiaries, the company engages in the development, manufacture, and commercialization of a range of pharmaceutical and healthcare products. If you look at the long term chart, you will see that the stock channels between approximately $7 and $14, and has done so for a couple years. The stock is now at the bottom of the channel (last trade was $7.09), just in time for flu season. Here is what you need to know: <> P/E Ratio (TTM) of just 10.41, versus the industry's average of 24.1 <> Has an incredibly consistent record of increasing sales at 50...
|
AOB- A Chinese up and coming company
AOB
|
|
|
-40.39%
in
436 days
This is a very good little company. When I first came across this company it trading on the Pink Sheets and had a market cap of about 40 million dollars. They were a typical pink sheeter that had done a reverse merger and gone the typical pipe financing route. When I first met them I was very dubious of their credibility but I stayed with it and worked through a painful series of one on one meetings in broken English. I made a small investment because something told me these guys were for real.
Fast forward a few years, today they are listed on the NYSE and I have grown...
|
Chinese Pharmaceutical Play
AOB
|
|
|
-67.82%
in
781 days
AOB, American Oriental Bioengineering is a major player in huge Chinese market of pharmaceuticals and nutraceuticals. They make prescription and otc products herbal and traditional. Great fundamentals TTM EPS gorwth 56%, ROE 23%, qtr earnings growth 66%, 13 week price performance rank 90% for sector, and institutional ownership is 48%, 105 higher than industry sector and growing. So fundamentals and technicals strong and institutional pumping in investment dollars makes this a strong buy.
|
AOB - American Oriental Bioengineering
AOB
-61.39%
in
807 days
<> Strong fundamentals held back by strong shorts in the recent months has given way…. the squeeze is on. The underlying fundamentals are finally supporting a break out. Outstanding recent quarterly announcement plus two acquisitions not factored into the EPS are in the midst of closing. They have completed one acquisition and have one to go adding approximately 21 million in revenue per year. The last acquisition is expected to close at the end of third quarter. AOB in past acquisitions have been able to triple the revenues of the acquired companies by pumping their products into their <><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><>...
|
From the Blogosphere
American Oriental Disappoints – Analyst Blog
|
|
|
American Oriental Bioengineering’s (AOB) third quarter earnings per share came in at 13 cents, well below the Zacks Consensus Estimate of 19 cents and 21 cents in the year ago period. The company derives revenues from two operating segments – Manufacturing and Distribution. During the quarter, Manufacturing accounted for more than 95% of the company’s total revenues.
<>Total revenues increased 11.7% year over year to $78.8 million. American Oriental records Manufacturing revenues from two sources – Pharmaceutical and Nutraceutical products. Both sources recorded an increase of 6.3% to $<><><><>< /><>< /><>< /><><>< /><>< /><>< />< />...
|
AOB's Cash Generation Provides Backstop to Earnings Miss
American Oriental Bioengineering's (AOB) 3Q09 results missed expectations and prior guidance as key risk factors came to bear. The company also announced a relatively small restatement to prior results following the engagement of Ernst & Young as its auditor (some minor housekeeping is okay, in our view). We noted in our post last week that short interest was elevated, but we hoped the shorts would be wrong this time.
We include more details on our blog, but a few key figures:
|
AOB's Disclosures Concerning Director Cosimo Patti Appear Incomplete
Editor's note: All links are to PDF file downloads. Public filings show that Cosimo Patti, a director of American Oriental Bioengineering, Inc. (NYSE: AOB), received compensation not disclosed by AOB through consulting fees paid to Technology Integration Group, Inc. ("TIG"), a penny stock company where Mr. Patti was the 91% owner and sole employee. Mr. Patti has been an AOB director since September 27, 2004, and serves on the AOB board's audit, compensation, and nominating and corporate governance committees. Mr. Patti is presented as an "independent" director.
|
AOB Chairman's Questionable Second Passport and Potential Undisclosed Conflicts of Interest
The chairman and CEO of American Oriental Bioengineering, Inc. (NYSE: AOB), Shujun "Tony" Liu, used a second passport from the Commonwealth of Dominica in addition to his Chinese passport in corporate filings with the Hong Kong Companies Registry ("HKCR"). Liu has appeared in publicly-available HKCR filings as a director for at least nine different Hong Kong companies. <>Five of these companies appear to be indirect subsidiaries of AOB, but only one of them has been listed as a subsidiary in AOB's SEC filings. All of AOB's subsidiaries should be disclosed in SEC filings. The absence of adequat...
|
Don't Dismiss American Oriental Bioengineering's Franchise Value
This week presented much to digest regarding American Oriental Bioengineering (AOB). The company reported June quarter results, lowered 2009 net income guidance, launched new product (Jingwei Capsules), and responded to a short seller's research report published on 8/5/09 that significantly pressured AOB's shares. <>Results reported this morning fell slightly short of Wall Street expectations, posting revenue of $71.2 million (+21% Y/Y) and diluted earnings per share of $0.17 compared to expectations of $74.9 million (+27% Y/Y) and $0.18, respectively. Operating margins declined to 25.7% in th...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Visit streetinsider.com
More Resources
|
About American Oriental Bioengineering Inc
- Answers.com
